Reparixin as a Potential Antiepileptogenic Agent: Modulation of the CXCL1–CXCR1/2 Axis and Seizure Activity in a Kindling Rat Model of Temporal Lobe Epilepsy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072831 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Nihan Çarçak und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Istanbul University, 34116 Istanbul, Türkiye. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Chemokine CXCL1, Kindling, Neurologic, Receptors, Interleukin-8B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministery of Health of Italy, Dompé Farmaceutici S.p.A., Ladarixin as new Juvenile Diabetes Inhibitory Agent (LJDIA).
Abstract (Originalsprache)
Chemokine (CXC motif) ligand 8 (CXCL8) is a pro-inflammatory chemokine binding to CXC motif receptors 1/2 (CXCR1/2). Patients with temporal lobe epilepsy (TLE) exhibit increased serum CXCL8 levels. CXC motif ligand 1 (CXCL1), a murine ortholog of CXCL8, has been implicated in seizure generation and neuronal loss. This study evaluated the antiepileptogenic and antiseizure effects of reparixin in amygdaloid kindling rat model of TLE. Reparixin was administered during the kindling period for 14 days, and seizures were induced twice daily via electrical stimulation. To assess the antiseizure effects, reparixin was administered to fully kindled animals, and stimulations were performed 24 and 48 h later. Levetiracetam, a broad-spectrum antiseizure drug, was administered intraperitoneally (i.p.) as positive control 1 h before each stimulation. Reparixin delayed secondary seizure generalization during kindling. Reparixin reduced seizure severity and after-discharge duration in fully kindled animals at 24 h from treatment initiation. CXCR1/2 and protein kinase B pathway proteins exhibited no significant changes; reparixin reduced the phospho-extracellular signal-regulated kinase (pERK)/ERK ratio in the cortex and hippocampus. CXCL1 expression was significantly decreased in the cortex. Reparixin exhibited antiepileptogenic and partial antiseizure effects by modulating the CXCL1–CXCR1/2 axis and reducing ERK signaling. Already in clinical trials on respiratory diseases, reparixin could be repurposed for epilepsy therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Pharmacy, Istanbul University, 34116 Istanbul, Türkiye.
- Department of Neuroscience, Institute of Health Sciences, Acibadem Mehmet Ali Aydinlar University, 34684 Istanbul, Türkiye.
- Department of Pharmacology, Institute of Health Sciences, Istanbul University, 34126 Istanbul, Türkiye.
- Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, 34093 Istanbul, Türkiye.
- R&D, Dompé Farmaceutici SpA, 67100 L'Aquila, Italy.
- Department of Medical Pharmacology, School of Medicine, Acibadem Mehmet Ali Aydinlar University, 34684 Istanbul, Türkiye.
ORCID-Profile: Nihan Çarçak, Nursima Mutlu, Elif Tuğçe Erdeve, Talat Taygun Turan, Canan Ulusoy, Cem İsmail Küçükali, Laura Brandolini, Andrea Aramini, Marcello Allegretti, Filiz Onat, Lidia De Filippis
Förderung
- Ministery of Health of Italy
- Dompé Farmaceutici S.p.A.
- Ladarixin as new Juvenile Diabetes Inhibitory Agent (LJDIA)
Zitieren
APA
Çarçak, N., Mutlu, N., Erdeve, E. T., Turan, T. T., Sarıyıldız, Ö., Ulusoy, C., Şanlı, E., Tüzün, E., Küçükali, C. İ., Brandolini, L., Aramini, A., Allegretti, M., Onat, F., & De Filippis, L. (2025). Reparixin as a Potential Antiepileptogenic Agent: Modulation of the CXCL1–CXCR1/2 Axis and Seizure Activity in a Kindling Rat Model of Temporal Lobe Epilepsy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072831
Vancouver
Çarçak N, Mutlu N, Erdeve ET, Turan TT, Sarıyıldız Ö, Ulusoy C, et al. Reparixin as a Potential Antiepileptogenic Agent: Modulation of the CXCL1–CXCR1/2 Axis and Seizure Activity in a Kindling Rat Model of Temporal Lobe Epilepsy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072831
BibTeX
@article{arak2025,
author = {Çarçak, Nihan and Mutlu, Nursima and Erdeve, Elif Tuğçe and Turan, Talat Taygun and Sarıyıldız, Özge and Ulusoy, Canan and Şanlı, Elif and Tüzün, Erdem and Küçükali, Cem İsmail and Brandolini, Laura and Aramini, Andrea and Allegretti, Marcello and Onat, Filiz and De Filippis, Lidia},
title = {Reparixin as a Potential Antiepileptogenic Agent: Modulation of the CXCL1–CXCR1/2 Axis and Seizure Activity in a Kindling Rat Model of Temporal Lobe Epilepsy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072831}
}
EUVIMED